Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

ermune.com">www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy and safety results the company has submitted in support of its NDA filing and currently intends to submit in support of its MAA filing.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" attached as Exhibit 99.3 to InterMune's Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... fundamental traits of a,tumor – how it avoids ... according to researchers from the,University of Southern California. ... cancers, indicate that,a technique for determining a tumor’s ... cancers. , ,In the July 1 issue ...
... - Nymox,Pharmaceutical Corporation (NASDAQ: NYMX) today announced ... of NX-1207 for,benign prostatic hyperplasia (BPH) will ... the American Urological Association Meeting in,Boston in ... clinical,research investigators from U.S. clinical trials of ...
Cached Medicine Technology:Researchers Discover Method for Identifying How Cancer Evades the,Immune System 2Researchers Discover Method for Identifying How Cancer Evades the,Immune System 3Clinical Data From Nymox BPH Drug To Be Presented at American,Urological Association Meeting 2
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
(Date:8/28/2015)... ... , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse ... Mission” benefit concert in Mendon, IL. Held in the Show Barn at the Adams ... education programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... / Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. Elyson and ... just $199, patients can currently receive a one hour treatment of this teeth whitening ... it includes a number of unique features that can turn teeth up to nine ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... ... and their families asked to share stories around men,s health issues , ... Minneapolis, Minnesota (PRWEB) June 15, 2009 -- In ... Scoop is calling on men and their family members to share their health-related experiences ...
... , CHICAGO, June 15 The following statement is attributable ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ... honored that President Obama will speak directly to physicians at ... to health reform this year that provides all Americans with ...
... announced today the first commercial, plant-based diamine oxidase (DAO). Dr. ... that this new diamine oxidase is orders of magnitude more ... is available as a lyophilized powder. Price will be $200 ... test assays to detect spoilage by the presence of histamines ...
... To Be Released Tuesday Show Employer Health Mandate Would Help ... , WASHINGTON, June 15 Hundreds of economists will ... nation,s health care system, and health care experts will release ... a conference call with reporters on Tuesday. , , ...
... delivery of gene therapy suppresses tumors in mice , ... able to fight lung cancer using gene therapy delivered by ... lung cancer that were treated with a vaporized viral vector ... than untreated mice. , Researchers also found that treated mice ...
... JOLLA, Calif., June 15 Transdel Pharmaceuticals, Inc. (OTC ... developing non-invasive, topically administered products, announced that they anticipate ... of Ketotransdel(R) during the third quarter of 2009. ... of a randomized, double-blind, placebo controlled trial to evaluate ...
Cached Medicine News:Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 2Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 3Health News:AMA Committed to Health Reform, Welcomes President Obama 2Health News:Coming Soon: Lung-Cancer Spray? 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... MacularProtect delivers levels of nutrients ... and macular health in the ... The National Eye Institute. MacularProtect ... lutein, an antioxidant found to ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: